Tag : 2025 ASCO

The use of primary cytoreductive surgery (PCS) for ovarian cancer has declined over the past decade, from 70% in 2010 to 37% in 2021, as neoadjuvant chemotherapy (NACT) emerged as an alternative to optimize surgical outcomes and reduce perioperative morbidity.